title: Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.
abstract: An essential component of allogeneic and autologous hematopoietic cell transplantation (HCT) is the conditioning regimen administered before the hematopoietic cell infusion. Early regimens relied on dose intensity, assuming that high-dose chemoradiotherapy would eliminate malignant disease and reinfusion of the graft would then restore hematopoiesis. However, as the contribution of graft-versus-tumor effects to the success of allogeneic HCT was recognized over time, in an effort to exploit these, many investigators lowered the dose of radiation and chemotherapeutic agents in the preparative regimen. This resulted in a major paradigm shift, and consequently, the pool of eligible patients underwent a remarkable expansion. In this article, we provide a review of the definition of high-dose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonly used agents and combinations, and the evolution of some early regimens. We also provide a brief review of the toxicities associated with these regimens.
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College of Cornell University, New York, NY;
authors.forename: Boglarka
authors.initials: B
authors.lastname: Gyurkocza
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA; and University of Washington School of Medicine, Seattle, WA.
authors.forename: Brenda M
authors.identifier: http://orcid.org/0000-0002-9767-9739
authors.initials: BM
authors.lastname: Sandmaier
mesh_terms: D064591:Allografts; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D064592:Autografts; D002986:Clinical Trials as Topic; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000639:trends; D006801:Humans; D019653:Myeloablative Agonists / Q000627:therapeutic use; D016499:Radioimmunotherapy; D019172:Transplantation Conditioning / Q000379:methods* / Q000639:trends; D014916:Whole-Body Irradiation
chemical_list: D000961:Antilymphocyte Serum; D019653:Myeloablative Agonists